Watching Protagenic Therapeutics, Inc.\new? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planProtagenic Therapeutics, Inc.\new
AI Executive Summary
AI-powered analysis of 10-Q filing content
Protagenic Therapeutics' cash position collapsed 62% quarter-over-quarter (from $1.51M to $566K) while stockholders' equity fell 34% to $1.72M, raising acute liquidity concerns given a quarterly net loss of $964K. R&D spending was slashed 72% year-over-year ($394K to $110K), suggesting a significant pullback in clinical/preclinical development activity, while unremediated material weaknesses in internal controls persist. Although the reported net loss improved sharply versus the prior-year quarter, this is driven almost entirely by the absence of one-time non-cash derivative and debt extinguishment charges rather than genuine operational improvement.
Red Flags Detected (6)
Cash declined 62% in a single quarter ($1,509,178 to $565,985), implying roughly 1-2 months of runway at current burn rate
R&D expenses cut 72% YoY ($394,112 to $109,925), atypical for a clinical-stage therapeutics company and possibly signaling program delays or funding constraints
Total stockholders' equity fell from $2,618,891 to $1,723,392 in one quarter
3 more red flags detected
Key Takeaways
Liquidity is the dominant near-term risk; current cash of $566K against a ~$960K quarterly operating loss implies imminent need for additional financing
Reduced R&D spend could reflect deliberate cost-cutting to preserve cash, but risks slowing therapeutic development timelines
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.